National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Clinical Announcement on
Intraperitoneal Therapy for Ovarian Cancer
    Posted: 01/04/2006    Updated: 10/04/2006



NCI Materials







Published Trial Results






Professional Education



Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Colorectal Cancer Drugs Require Careful Patient Selection

Cetuximab for Advanced Lung Cancer

Past Highlights
Related Pages
Search for Clinical Trials
NCI's PDQ® registry of cancer clinical trials.

Ovarian Cancer Home Page
NCI's gateway for information about ovarian cancer.
Published Trial Results

Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of Treatment
Abstract of article, from the Feb. 20, 2006, issue of the Journal of Clinical Oncology (J Clin Oncol. 2006 Feb 6; [Epub ahead of print]).

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Free access to the full article from the Jan. 5, 2006 issue of the New England Journal of Medicine. There is also an accompanying editorial.

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study
PDF of the full article from the Jan. 2006 issue of Gynecologic Oncology. There is also an accompanying editorial.

Intraperitoneal Cisplatin Versus No Further Treatment: 8-year results of EORTC 55875
Abstract of article, from the Nov.-Dec. 2003 issue of the International Journal of Gynecological Cancer (Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203).

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma
Abstract of article, from the Feb. 15, 2001, issue of the Journal of Clinical Oncology (J Clin Oncol. 2001 Feb 15;19(4):1001-7).

Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer
Abstract of article, from the Jan. 2001 issue of the International Journal of Gynecology & Obstetrics (Int J Gynaecol Obstet. 2001 Jan;72(1):55-60).

Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer
Abstract of article, from the Feb. 2000 issue of journal Gynecologic Oncology (Gynecol Oncol. 2000 Feb;76(2):157-62).

A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer
Abstract of article, from the 1999 issue of the journal Oncology (Oncology. 1999;56(4):291-6).

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
Abstract of article, from the Dec. 26, 1996, issue of the New England Journal of Medicine (N Engl J Med. 1996 Dec 26;335(26):1950-5).

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov